Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EPS (Basic) (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of EPS (Basic) readings, the most recent being $0.52 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 10.64% to $0.52 in Q1 2026 year-over-year; TTM through Mar 2026 was $1.81, a 9.7% increase, with the full-year FY2025 number at $1.75, up 26.81% from a year prior.
  • EPS (Basic) hit $0.52 in Q1 2026 for Catalyst Pharmaceuticals, up from $0.43 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.52 in Q1 2026 to a low of -$0.29 in Q3 2023.
  • Median EPS (Basic) over the past 5 years was $0.35 (2024), compared with a mean of $0.3.
  • Biggest five-year swings in EPS (Basic): crashed 231.82% in 2023 and later skyrocketed 227.59% in 2024.
  • Catalyst Pharmaceuticals' EPS (Basic) stood at $0.24 in 2022, then skyrocketed by 37.5% to $0.33 in 2023, then surged by 39.39% to $0.46 in 2024, then decreased by 6.52% to $0.43 in 2025, then grew by 20.93% to $0.52 in 2026.
  • The last three reported values for EPS (Basic) were $0.52 (Q1 2026), $0.43 (Q4 2025), and $0.43 (Q3 2025) per Business Quant data.